New Hepatitis B drug approved by US FDA offers patients a chance to ditch lifelong medication
The FDA approved GSK's Hibsago (bepirovirsen), a new chronic hepatitis B treatment that may allow some patients to stop therapy. It's used with existing antivirals in adults without cirrhosis. Clinical trials showed 19% of patients maintained viral control after stopping treatment. GSK expects peak sales over £2 billion. The drug was licensed from Ionis Pharmaceuticals.
How this was made
The 30-second read
Why it matters
GSK gains a novel asset with a potential multi‑billion revenue stream, likely boosting its valuation and influencing the broader antiviral sector.
Market read
First‑in‑class hepatitis B therapy approval is a material event for GSK and the biotech sector.
What to watch
Reimbursement negotiations and competition from Ionis‑licensed candidates may affect long‑term sales.
Background
The article details the FDA's first approval of an antisense oligonucleotide for chronic hepatitis B, including trial results, safety warnings, and GSK's commercial expectations.
Ticker impact
FDA approval of Hibsago (bepirovirsen) gives GSK a new chronic hepatitis B therapy, its first antisense drug and a potential $2B revenue driver.
likely upward pressure as the market prices in the new product launch
Regulatory clearance is a material catalyst; GSK expects >£2 bn annual sales, and the market typically reacts positively to first‑in‑class approvals.
Market effects
strengthens the hepatitis B therapeutic space and may pressure peers like Gilead and Novartis.
positive for UK‑listed pharma stocks and US ADRs.
adds a new first‑in‑class antiviral, relevant to global healthcare investors.
Counterpoint
If the drug's safety warnings limit uptake, the upside could be muted.
Key entities
- companyGSK plc
Pharmaceutical company receiving FDA approval for Hibsago.
- regulatorFDA
U.S. agency that approved the drug.
